{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:20:29Z","timestamp":1789132829410,"version":"build-2803163510"},"reference-count":67,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.psychres.2011.07.008","type":"journal-article","created":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T22:38:05Z","timestamp":1312238285000},"page":"200-207","source":"Crossref","is-referenced-by-count":13,"title":["Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder"],"prefix":"10.1016","volume":"189","author":[{"given":"William Victor","family":"Bobo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bonaccorso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karuna","family":"Jayathilake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert Yale","family":"Meltzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2011.07.008_bb0005","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4088\/JCP.v65n0219","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"65","year":"2004","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.psychres.2011.07.008_bb0010","first-page":"S62","article-title":"Diagnosis and classification of diabetes mellitus","volume":"33","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.psychres.2011.07.008_bb0015","doi-asserted-by":"crossref","first-page":"862","DOI":"10.2337\/diabetes.54.3.862","article-title":"Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs","volume":"54","author":"Ader","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.psychres.2011.07.008_bb0020","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2011.07.008_bb0025","series-title":"The Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994"},{"key":"10.1016\/j.psychres.2011.07.008_bb0030","doi-asserted-by":"crossref","first-page":"598","DOI":"10.4088\/JCP.v64n0516","article-title":"Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics","volume":"64","author":"Atmaca","year":"2003","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.psychres.2011.07.008_bb0035","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4088\/JCP.v62n0404","article-title":"Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone","volume":"62","author":"Basson","year":"2001","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.psychres.2011.07.008_bb0040","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0920-9964(02)00158-5","article-title":"Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment","volume":"59","author":"Baymiller","year":"2003","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.psychres.2011.07.008_bb0045","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/JCP.0b013e318166c4f7","article-title":"Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions","volume":"28","author":"Birkenaes","year":"2008","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.psychres.2011.07.008_bb0050","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1161\/01.CIR.0000038496.57570.06","article-title":"Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI)","volume":"106","author":"Bittner","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.psychres.2011.07.008_bb0055","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1161\/01.CIR.0000038496.57570.06","article-title":"Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI)","volume":"106","author":"Bittner","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.psychres.2011.07.008_bb0060","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.pharmthera.2007.10.004","article-title":"Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy","volume":"117","author":"Chapman","year":"2008","journal-title":"Pharmacology and Therapeutics"},{"key":"10.1016\/j.psychres.2011.07.008_bb0065","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00213-004-1949-9","article-title":"Pharmacogenetics of antipsychotic-induced weight gain","volume":"174","author":"Correll","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.psychres.2011.07.008_bb0070","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/pds.1424","article-title":"Cardiovascular risks of atypical antipsychotic drug treatment","volume":"16","author":"Drici","year":"2007","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"10.1016\/j.psychres.2011.07.008_bb0075","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1176\/appi.ajp.158.10.1719","article-title":"Association of olanzapine-induced weight gain with an increase in body fat","volume":"158","author":"Eder","year":"2001","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2011.07.008_bb0080","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1176\/appi.ajp.158.10.1719","article-title":"Association of olanzapine-induced weight gain with an increase in body fat","volume":"158","author":"Eder","year":"2001","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2011.07.008_bb0085","doi-asserted-by":"crossref","first-page":"806","DOI":"10.4088\/JCP.09m05107yel","article-title":"Trigylceride\/high-density lipoprotein cholesterol ratio: a surrogate to predict insulin resistance and low-density lipoprotein cholesterol particle size in nondiabetic patients with schizophrenia","volume":"72","author":"Fan","year":"2011","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.psychres.2011.07.008_bb0090","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1161\/01.CIR.94.10.2381","article-title":"Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP)","volume":"94","author":"Frost","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.psychres.2011.07.008_bb0095","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1161\/01.CIR.94.10.2381","article-title":"Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP)","volume":"94","author":"Frost","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.psychres.2011.07.008_bb0100","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1176\/appi.ajp.162.1.118","article-title":"Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis","volume":"162","author":"Graham","year":"2005","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2011.07.008_bb0105","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1176\/appi.ajp.162.1.118","article-title":"Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis","volume":"162","author":"Graham","year":"2005","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2011.07.008_bb0110","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1176\/appi.ajp.162.1.118","article-title":"Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis","volume":"162","author":"Graham","year":"2005","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2011.07.008_bb0115","doi-asserted-by":"crossref","first-page":"18B","DOI":"10.1016\/S0002-9149(98)00033-2","article-title":"Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome","volume":"81","author":"Grundy","year":"1998","journal-title":"The American Journal of Cardiology"},{"key":"10.1016\/j.psychres.2011.07.008_bb0120","doi-asserted-by":"crossref","first-page":"18B","DOI":"10.1016\/S0002-9149(98)00033-2","article-title":"Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome","volume":"81","author":"Grundy","year":"1998","journal-title":"The American Journal of Cardiology"},{"key":"10.1016\/j.psychres.2011.07.008_bb0125","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/01.CIR.0000111245.75752.C6","article-title":"Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute\/American Heart Association conference on scientific issues related to definition","volume":"109","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.psychres.2011.07.008_bb0130","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/0269881105058378","article-title":"Weight change with atypical antipsychotics in the treatment of schizophrenia","volume":"19","author":"Haddad","year":"2005","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.psychres.2011.07.008_bb0135","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1038\/sj.npp.1301392","article-title":"Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients","volume":"32","author":"Haupt","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2011.07.008_bb0140","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archpsyc.62.1.19","article-title":"Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis","volume":"62","author":"Henderson","year":"2005","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.psychres.2011.07.008_bb0145","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1176\/appi.ajp.157.6.975","article-title":"Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study","volume":"157","author":"Henderson","year":"2000","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2011.07.008_bb0150","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.4088\/JCP.v65n1214","article-title":"Weight gain during treatment of bipolar I patients with olanzapine","volume":"65","author":"Hennen","year":"2004","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.psychres.2011.07.008_bb0155","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1520-037X.2002.00980.x","article-title":"Perspectives: the significance of measuring non-HDL-cholesterol","volume":"5","author":"Hirsch","year":"2002","journal-title":"Preventive Cardiology"},{"key":"10.1016\/j.psychres.2011.07.008_bb0160","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.npp.1301209","article-title":"Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects","volume":"32","author":"Houseknecht","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2011.07.008_bb0165","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1161\/01.CIR.97.11.1029","article-title":"Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study","volume":"97","author":"Jeppesen","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.psychres.2011.07.008_bb0170","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1161\/01.CIR.97.11.1029","article-title":"Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study","volume":"97","author":"Jeppesen","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.psychres.2011.07.008_bb0175","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1161\/01.CIR.97.11.1029","article-title":"Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study","volume":"97","author":"Jeppesen","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.psychres.2011.07.008_bb0180","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1001\/archinte.161.3.361","article-title":"Low triglycerides-high high-density lipoprotein cholesterol and risk of ischemic heart disease","volume":"161","author":"Jeppesen","year":"2001","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.psychres.2011.07.008_bb0185","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1001\/archinte.161.3.361","article-title":"Low triglycerides-high high-density lipoprotein cholesterol and risk of ischemic heart disease","volume":"161","author":"Jeppesen","year":"2001","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.psychres.2011.07.008_bb0190","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1001\/archinte.161.3.361","article-title":"Low triglycerides-high high-density lipoprotein cholesterol and risk of ischemic heart disease","volume":"161","author":"Jeppesen","year":"2001","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.psychres.2011.07.008_bb0195","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/10401230209147399","article-title":"Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases","volume":"14","author":"Jin","year":"2002","journal-title":"Annals of Clinical Psychiatry"},{"key":"10.1016\/j.psychres.2011.07.008_bb0200","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/bmj.322.7277.15","article-title":"Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk)","volume":"322","author":"Khaw","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.psychres.2011.07.008_bb0205","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4088\/JCP.v62n0204","article-title":"Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia","volume":"62","author":"Kinon","year":"2001","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.psychres.2011.07.008_bb0210","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/01.jcp.0000161501.65890.22","article-title":"Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders","volume":"25","author":"Kinon","year":"2005","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.psychres.2011.07.008_bb0215","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/01.jcp.0000161501.65890.22","article-title":"Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders","volume":"25","author":"Kinon","year":"2005","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"Suppl. 1","key":"10.1016\/j.psychres.2011.07.008_bb0220","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1046\/j.1462-8902.2003.0310.x","article-title":"Lipoprotein abnormalities and their consequences for patients with type 2 diabetes","volume":"5","author":"Krentz","year":"2003","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.psychres.2011.07.008_bb0225","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0924-977X(00)00127-9","article-title":"New onset diabetes and atypical antipsychotics","volume":"11","author":"Liebzeit","year":"2001","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2011.07.008_bb0230","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2337\/diacare.26.1.16","article-title":"Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study","volume":"26","author":"Lu","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.psychres.2011.07.008_bb0235","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.amjcard.2005.03.085","article-title":"Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?","volume":"96","author":"McLaughlin","year":"2005","journal-title":"The American Journal of Cardiology"},{"key":"10.1016\/j.psychres.2011.07.008_bb0240","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.amjcard.2005.03.085","article-title":"Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?","volume":"96","author":"McLaughlin","year":"2005","journal-title":"The American Journal of Cardiology"},{"key":"10.1016\/j.psychres.2011.07.008_bb0245","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.amjcard.2005.03.085","article-title":"Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?","volume":"96","author":"McLaughlin","year":"2005","journal-title":"The American Journal of Cardiology"},{"key":"10.1016\/j.psychres.2011.07.008_bb0250","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.amjcard.2005.03.085","article-title":"Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?","volume":"96","author":"McLaughlin","year":"2005","journal-title":"The American Journal of Cardiology"},{"key":"10.1016\/j.psychres.2011.07.008_bb0255","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s002130000639","article-title":"Insulin and leptin levels in patients with schizophrenia or related psychoses\u2014a comparison between different antipsychotic agents","volume":"154","author":"Melkersson","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.psychres.2011.07.008_bb0260","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1017\/S1461145705005183","article-title":"Focus on the metabolic consequences of long-term treatment with olanzapine, quetiapine and risperidone: are there differences?","volume":"8","author":"Meltzer","year":"2005","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2011.07.008_bb0335","unstructured":"Meltzer, H.Y., Bonaccorso, S., Bobo, W.V., Chen, Y., Jayathilake, K., in press. A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation. Journal of Clinical Psychiatry."},{"key":"10.1016\/j.psychres.2011.07.008_bb0265","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4088\/JCP.v63n0509","article-title":"A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1year","volume":"63","author":"Meyer","year":"2002","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.psychres.2011.07.008_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2004.01.014","article-title":"The effects of antipsychotic therapy on serum lipids: a comprehensive review","volume":"70","author":"Meyer","year":"2004","journal-title":"Schizophrenia Research"},{"issue":"Suppl. 1","key":"10.1016\/j.psychres.2011.07.008_bb0275","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"issue":"Suppl. 1","key":"10.1016\/j.psychres.2011.07.008_bb0280","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.psychres.2011.07.008_bb0285","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archpsyc.59.4.337","article-title":"Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia","volume":"59","author":"Newcomer","year":"2002","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.psychres.2011.07.008_bb0290","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1046\/j.1467-789x.2001.00031.x","article-title":"Beyond body mass index","volume":"2","author":"Prentice","year":"2001","journal-title":"Obesity Reviews"},{"key":"10.1016\/j.psychres.2011.07.008_bb0295","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1001\/jama.295.14.1688","article-title":"Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c","volume":"295","author":"Saudek","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.psychres.2011.07.008_bb0300","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa0908359","article-title":"Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults","volume":"362","author":"Selvin","year":"2010","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.psychres.2011.07.008_bb0305","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.162.2.249","article-title":"The distribution of adipose tissue in female in-patients receiving psychotropic drugs","volume":"162","author":"Stedman","year":"1993","journal-title":"The British Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2011.07.008_bb0310","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.162.2.249","article-title":"The distribution of adipose tissue in female in-patients receiving psychotropic drugs","volume":"162","author":"Stedman","year":"1993","journal-title":"The British Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2011.07.008_bb0315","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1176\/appi.ajp.162.6.1217","article-title":"Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications","volume":"162","author":"Straker","year":"2005","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.psychres.2011.07.008_bb0320","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/YIC.0b013e32833bc60d","article-title":"MTHFR genotype and differential evolution of metabolic parameters after initiation of a second generation antipsychotic: an observational study","volume":"25","author":"van","year":"2010","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1016\/j.psychres.2011.07.008_bb0325","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.psychres.2010.03.011","article-title":"Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia","volume":"177","author":"Vancampfort","year":"2010","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.psychres.2011.07.008_bb0330","doi-asserted-by":"crossref","first-page":"856","DOI":"10.4088\/JCP.v63n1002","article-title":"The effects of novel antipsychotics on glucose and lipid levels","volume":"63","author":"Wirshing","year":"2002","journal-title":"The Journal of Clinical Psychiatry"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178111005129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178111005129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T13:43:16Z","timestamp":1686231796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178111005129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0165178111005129"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2011.07.008","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}